Don't Jump to an SGLT2 Inhibitor for Heart Failure

You'll hear debate about whether to use an SGLT2 inhibitor (Farxiga, etc) to treat heart patients withOUT diabetes.

Prior evidence shows that patients WITH diabetes and CV disease or CV risks have fewer heart failure hospitalizations with Farxiga (dapagliflozin), Invokana (canagliflozin), or Jardiance (empagliflozin).

New evidence suggests Farxiga may benefit some heart failure patients...whether or not they have type 2 diabetes.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote